Differential regulation of aldose reductase expression during macrophage polarization depends on hyperglycemia

Abstract

Aldose reductase (AR; gene AKR1B1) is the rate-limiting enzyme of the polyol pathway and has been associated with diabetes and atherosclerosis. Here, we sought to identify the mechanisms underlying differential AR expression in human atherosclerotic plaque macrophages. In vitro, M1-polarized human monocyte-derived macrophages expressed significantly higher levels of AKR1B1 mRNA and AR protein compared with M2-polarized macrophages. AR activity was significantly higher in M1 macrophages. AKR1B1 mRNA expression correlated positively with the M1 marker TNF (r = 0.430, P = 0.006) and negatively with the M2 marker MRC1 (r = −0.443, P = 0.044). Increased AR expression in M1 macrophages depended on hyperglycemia. Concomitantly, expression of SLC2A1 (coding for the Glc transporter GLUT-1) was significantly higher in M1 than in M2 macrophages. Pharmacological inhibition of GLUT-1 using STF-32 completely abrogated Glc-induced AR up-regulation in M1 macrophages. When analyzing AR expression in post-mortem coronary artery plaque macrophages, a history of diabetes was associated with a significantly increased proportion of CD68⁺AR⁺⁺ macrophages, supporting the in vivo relevance of our in vitro findings. We demonstrate that the phenotype of atherosclerotic plaque macrophages may be affected by cardiovascular risk factors such as hyperglycemia. Our data illustrate the complex interplay between systemic and local factors in atherogenesis.

Keywords

Atherosclerosis coronary artery disease macrophage diabetes mellitus aldose reductase

Introduction

Atherosclerosis is an inflammatory disease of the arterial wall.¹ During the course of atherogenesis, blood monocytes adhere to the endothelium, transmigrate into the subendothelial space and differentiate toward macrophages.¹ This differentiation process is modulated by cytokines, chemokines and lipoproteins within the subendothelial space. Depending on the local micromilieu, it may result in differentially polarized macrophages.^2,3 Accordingly, the cells may assume different polarization phenotypes: the pro-inflammatory M1 phenotype induced by IFN-γ and LPS, and the rather anti-inflammatory M2 phenotype induced by Th2 cytokines such as IL-4 represent the extremes of this polarization spectrum.⁴ Intermediate or additional polarization types may also occur within atherosclerotic lesions.^2,3

Diabetes is one of the most important risk factors promoting atherogenesis and plaque destabilization.^5,6 The underlying mechanisms are manifold.^6,7 One mechanism associated with hyperglycemia seems to be the induction of aldose reductase (AR), the rate-limiting enzyme of the polyol pathway. Under normoglycemia, AR is involved in detoxyfication of aldehydes.^8,9 Based on its Km of 0.66 µmol/l for D-Glc, Glc may also be a substrate for AR under normoglycemic conditions.^10,11 With raising Glc concentrations, increasing amounts of Glc may be shunted into the polyol pathway leading to increased Fru concentrations and NADPH consumption.⁷ Accordingly, AR has been linked to diabetic complications such as cataract,¹² nephropathy¹³ and neuropathy.¹⁴

We have previously demonstrated AR expression in human atherosclerotic plaque macrophages that is synergistically increased by both high levels of oxidized LDL and Glc.¹⁵ Interestingly, AR expression was not consistently found in all plaque macrophages. We therefore hypothesized that AR expression may be restricted to a certain macrophage polarization type. Here, we investigated AR expression and activity in differentially polarized monocyte-derived macrophages in vitro and in human post-mortem coronary arteries.

Material and methods

Monocyte-derived human macrophages

The study was approved by the institutional review committee (S-045/2011). All participants gave informed consent. Monocyte-derived macrophages were generated in serum-free media with M-CSF as described previously.^16–18 M1 and M2 polarization of macrophages was induced as described previously.¹⁹ Recombinant human M-CSF (Cat. No. 300-25), IFN-γ (Cat. No. 300-02,) and IL-4 (Cat. No. AF-200-04) were purchased from Peprotech (Wiesbaden, Germany). LPS (Cat. No. L4516-1 mg) was purchased from Sigma (Taufkirchen, Germany). To study the effects of hypo- or hyperglycemia, cells were kept in media containing 0, 5 or 30 mmol/l Glc for the last 18 h of cell culture. To study the role of the Glc transporter GLUT-1, STF-32, was used as a specific GLUT-1 inhibitor.²⁰

Quantitative RT-PCR

Quantitative PCR was performed as described previously.¹⁸ Primer sequences were obtained from Primer Bank:²¹ AKR1B1 forward AGTCGGGCAATGTGGTTCCC, AKR1B1 reverse GGATTAACTTCTCCTGAGTG; TNF forward TCTTCTCGAACCCCGAGTGA, TNF reverse CCTCTGATGGCACCACCA G,;IL6 forward AAATTCGGTACATCCTCGACGG, IL6 reverse GGAAGGTTCAGGTTGTTTTCTGC; MRC1 forward TCCGATGGGTGTCCGAATCT, MRC1 reverse ACAGGCATAGAGAGTGATAGCAA; CD36 forward GCCAAGGAAAATGTAACCCAGG, CD36 reverse GCC TCT GTT CCA ACT GAT AGT GA; SLC2A1 forward GGCCAAGAGTGTGCTAAAGAA, SLC2A1 reverse ACAGCGTTGATGCCAGACAG; SLC2A3 forward GCTGGGCATCGTTGTTGGA, SLC2A3 reverse GCACTTTGTAGGATAGCAGGAAG; SLC2A5 forward GAGGCTGACGCTTGTGCTT, SLC2A5 reverse CCACGTTGTACCCATACTGGA; GAPDH forward GGCTCATGACCACAGTCCAT, GAPDH reverse GCCTGCTTCACCACCTTCT. Gene expression was calculated using GAPDH as a housekeeping gene using the delta Ct method.²²

Flow cytometry

Intracellular flow cytometry was performed as described previously.¹⁸ AR was stained using a goat anti-human polyclonal IgG Ab (Cat. No. SC-17732, clone N-20; Santa Cruz, Heidelberg, Germany), a Cy3-conjugated mouse anti-goat Anti-Goat IgG (Jackson ImmunoResearch, Suffolk, UK) was used as secondary Ab. For control stainings, the first Ab was left out.

AR activity assay

AR activity was measured as described previously.^8,15,23 Briefly, activity was measured spectrophotometrically by determination of the decrease in absorbance at 340 nm in the absence and presence of glyceraldehyde as substrate reflecting the consumption of NADPH (Prod. No. N5130; Sigma).^8,23,24 AR activity was normalized to protein content and expressed in mU/µg (nmol NADPH oxidized per min per µg protein).

Immunofluorescence

Human post-mortem coronary arteries were obtained from the University of Virginia Department of Pathology/Tissue bank. Immunofluorescence staining for AR and CD68 was performed as described previously.¹⁵ Depending on their staining pattern, macrophages were classified CD68⁺AR⁻, CD68⁺AR⁺ and CD68⁺AR⁺⁺. AR⁺ and AR⁺⁺ were determined through semiquantitative analysis by a reviewer blinded in regards to the patients’ diagnoses.

Statistics

Quantitative PCR and flow cytometry data were analyzed by paired non-parametric Mann–Whitney testing. Multiple comparisons were done using the Kruskall–Wallis test with Dunn’s multiple comparison testing. Proportions were compared using χ²testing. All statistical analyses were performed using Prism (GraphPad Inc., La Jolla, CA, USA). P < 0.05 was considered statistically significant.

Results

AR is differentially expressed in human atherosclerotic plaque macrophages

Macrophages have been demonstrated to be a key source of AR expression within atherosclerotic lesions.¹⁵ We have previously described differential AR expression in macrophages located within the intima, the adventitia, or perivascular fat.¹⁵ To better understand which conditions may regulate macrophage AR expression, we performed immunofluorescence staining of human post-mortem coronary arteries against CD68 and AR in different post-mortem donors. As shown in Figure 1, CD68⁺AR⁻, CD68⁺AR⁺ and CD68⁺AR⁺⁺ macrophages could be identified in most lesions. CD68⁺ cells were mostly AR⁺ or AR⁺⁺, with a rather small proportion of CD68⁺AR⁻ macrophages. The proportion of CD68⁺AR⁺ and CD68⁺AR⁺⁺ macrophages differed substantially between patients (2–69% for CD68⁺AR⁺ and 26–56% for CD68⁺AR⁺⁺; Figure 1b). Therefore, further experiments were conducted to elucidate the underlying reasons for differential AR expression in plaque macrophages.

Figure 1.

AR is differentially expressed in human atherosclerotic plaque macrophages. (a) Immunofluorescence staining of a post-mortem coronary artery against CD68 (green) and AR (red). DAPI (blue) as nuclear stain. Yellow arrow indicates a CD68⁺AR⁺⁺, orange arrow a CD68⁺AR⁺ and green arrow a CD68⁺AR⁻ macrophage. Scale bars indicate 100 µm. (b) Relative proportion of CD68⁺AR⁻ (green), CD68⁺AR⁺ (orange) and CD68⁺AR⁺⁺ (yellow) macrophages of all CD68⁺ plaque macrophages in post-mortem coronary arteries derived from eight different individuals. ‘n’ indicates the number of CD68⁺ macrophages analyzed.

AR is preferentially expressed by M1-polarized macrophages

In vitro, human monocyte-derived macrophages were polarized toward a M1 or M2 phenotype, as described previously.¹⁹ Successful M1 polarization was confirmed by increased IL6 and TNF expression, while M2 polarization was ascertained by increased CD36 and CD206 expression (Figure 2a,b).

Figure 2.

AR is preferentially expressed by M1 polarized macrophages. Gene expression of (a) M1 and (b) M2 markers in M1 or M2 polarized human monocyte-derived macrophages as determined by quantitative PCR. n = 6–9, *P < 0.05, **P < 0.01. (c) AKR1B1 gene expression in M1 and M2 polarized human monocyte-derived macrophages. n = 9, **P < 0.01. (d) Representative histogram of intracellular flow cytometry for AR in M1 (solid line) and M2 (dotted line) polarized human monocyte-derived macrophages. Bar graph summarizing the results of seven independent experiments. *P < 0.05. (e) AR activity as determined by a photometric assay in M1 and M2 polarized human monocyte-derived macrophages. n = 6, *P < 0.05.

AKR1B1 mRNA expression (coding for AR) was significantly higher in M1 macrophages (Figure 1c). Similarly, intracellular flow cytometry confirmed increased AR expression in M1 macrophages at the protein level (Figure 1d). In the same line, AR activity was significantly higher in M1 compared with M2 macrophages (Figure 1e).

The notion that AR expression is associated with M1 polarization was furthermore confirmed when correlating the expression levels of AKR1B1 with either TNF (M1 marker) or CD206 (M2 marker) in differentially polarized macrophages (Figure 2). These analyses clearly confirmed a positive correlation between AKR1B1 expression and M1 polarization (r = 0.540, P = 0.006), while there was a negative correlation between AKR1B1 expression and M2 polarization (r = −0.443, P = 0.044).

Differential AR expression between M1 and M2 macrophages depends on hyperglycemia

As many other in vitro models, our cell culture experiments employ hyperglycemic conditions (17.5 mmol/l Glc).¹⁵ However, it has been previously shown that macrophage AR expression is increased under hyperglycemic conditions with concentrations up to 30 mmol/l.¹⁵ To confirm these data and test whether hyperglycemia was also relevant for differential AR expression between M1 and M2 macrophages, monocyte-derived macrophages were polarized in vitro under hypoglycemia (0 mM) or severe hyperglycemia (30 mM). While increased Glc concentrations did not induce AR expression in M2 macrophages, there was a significant increase of AR expression with increasing Glc concentrations in M1 macrophages (P < 0.01; Figure 4a).

Figure 4.

Overexpression of AR in M1 macrophages depends on hyperglycemia. (a) Relative AKR1B1 expression in M1 (black circles) and M2 (open squares) polarized human monocyte-derived macrophages under hypo-, normo- or hyperglycemic conditions. Expression is shown normalized to the basal expression level in M1 or M2 macrophages under hypoglycemia. n = 6, **P < 0.01 vs. 0 mmol/l Glc. (b) Expression of SLC2A1, SLC2A3 and SLC2A5 (coding for GLUT-1, GLUT-2 and GLUT-5) in M1 and M2 polarized human monocyte-derived macrophages. n = 9, *P < 0.05. (c) AKR1B1 expression in M1 and M2 macrophages differentiated under hypoglycemic (0 mmol/l Glc) and hyperglycemic (30 mml/l Glc) conditions in the presence of STF-32, a specific pharmacological inhibitor of GLUT-1, or DMSO control. n = 3, *P < 0.05.

As AKR1B1 expression is under the control of an osmotic response element that is Glc sensitive,²⁵ we sought to test whether there were differences in Glc transporter expression between M1 and M2 macrophages. Three Glc transporters are known to be expressed in human macrophages, GLUT-1, GLUT-3 and GLUT-5.²⁶ In fact, SLC2A1 mRNA expression (coding for GLUT-1) was significantly higher in M1 macrophages. For SLCA3 and SLC3A5 (coding for GLUT-3 and GLUT-5, respectively), expression was slightly, but not significantly, higher in M1 macrophages (Figure 4b).

To test whether increase of GLUT-1 expression was causally involved in increased AR expression in M1 macrophages, STF-32 was used as a specific pharmacological inhibitor. While treatment macrophages with STF-32 completely inhibited Glc-induced AR up-regulation, it did not affect AR expression in M2 macrophages (Figure 4c). These data suggest that differential AR expression in plaque macrophages may at least partially depend on increased Glc levels.

Diabetic patients display a greater proportion of CD68⁺AR⁺⁺ macrophages than non-diabetic patients

Our in vitro data suggest that differential expression of AR between differentially polarized macrophages depends on hyperglycemia. Accordingly, high Glc levels as potentially seen in diabetic patients may result in a greater proportion of CD68⁺AR⁺⁺ plaque macrophages. We therefore tested whether there were any differences regarding the prevalence of CD68⁺AR⁻, CD68⁺AR⁺ and CD68⁺AR⁺⁺ plaque macrophages between diabetic and non-diabetic individuals.

While the percentage of CD68⁺AR^- macrophages was moderately higher in diabetic than in non-diabetic patients (increased by eight percentage points), the proportion of CD68⁺AR⁺⁺ was significantly higher (increased by 36 percentage points, P < 0.0001; Figure 5), supporting the in vitro findings of increased AR expression in M1 macrophages depending on hyperglycemic conditions.

Figure 3.

Correlation between AKR1B1 expression and polarization in human monocyte-derived macrophages. Correlation of AKR1B1, (a) TNF (marker for M1 polarization) or (b) MRC1 (marker for M2 polarization) mRNA expression in M1 (black circles) and M2 (open squares) polarized human monocyte-derived macrophages. n = 18–28.

Figure 5.

Coronary artery plaques from diabetic patients display a greater degree of macrophage heterogeneity regarding AR expression. Representative immunofluorescence stainings of post-mortem coronary arteries against CD68 (green) and AR(red) from (a) a non-diabetic and (b) a diabetic patient. DAPI (blue) as nuclear stain. Yellow arrows indicate CD68⁺AR⁺⁺, orange arrows CD68⁺AR⁺ and green arrows CD68⁺AR⁻ macrophages. Scale bars indicate 100 µm. (c) Relative proportions of a CD68⁺AR⁺⁺ (yellow), CD68⁺AR⁺ (orange) and CD68⁺AR⁻ macrophages in non-diabetic and diabetic individuals (P < 0.0001).

Discussion

Diabetes may promote atherogenesis and destabilization of atherosclerotic plaques by various mechanisms.^6,7 One of the mechanisms associated with hyperglycemia is the induction of AR, the rate-limiting enzyme of the polyol pathway. We have previously shown that a subset of human plaque macrophages expresses AR and that its expression is synergistically induced by hyperlipidemia and hyperglycemia.¹⁵ Here, we expand these findings by showing that AR expression is mainly found in M1 macrophages, while expression in M2 macrophages is rather low. Also, we find that differential AR expression depends on hyperglycemia, that is, with increasing Glc levels AR expression increases in M1 but not M2 macrophages. As underlying mechanism, we propose increased expression of the Glc transporter GLUT-1 in M1 macrophages facilitating Glc uptake and presumably inducing increased AR (AKR1B1) gene transcription. These in vitro data are complemented by immunofluorescence stainings from human post-mortem coronary arteries, in which diabetic patients show a significantly greater proportion of CD68⁺AR⁺⁺ plaque macrophages than non-diabetic individuals.

The pathophysiological relevance of macrophage heterogeneity in human atherosclerosis has clearly been recognized.^2,3 In 2006, Bouhlel et al.²⁷ demonstrated expression of both M1 and M2 markers within atherosclerotic lesions. Subsequent studies by Waldo et al.,²⁸ Bolye et al.,²⁹ our own group^30,31 and others have shown that other macrophage types induced by GM-CSF, hemorrhage or CXCL4 can be identified within atherosclerotic lesions. It is conceivable that plaque destabilization and rupture are promoted by a pro-inflammatory macrophage subset within the lesion. Thus, identification of pro-atherogenic macrophage phenotypes may be of diagnostic and therapeutic value when developing strategies to prevent plaque rupture and subsequent myocardial infarction.

Our data demonstrate that differential macrophage polarization may, in some cases, be affected by cardiovascular risk factors such as hyperglycemia. Thus, differential AR expression between M1 and M2 polarized macrophages clearly depends on hyperglycemic conditions. One explanation may be given by increased expression of GLUT-1 in M1 macrophages: GLUT-1 is one of the three major Glc transporters expressed by human macrophages.^26,32 Pharmacological inhibition of GLUT-1 completely abrogated Glc-dependent AR up-regulation; thus, increased GLUT-1 expression in M1 macrophages may lead to increased Glc uptake, which may, in turn, stimulate an osmotic response element that induces AR expression and activity.²⁵

This in vitro finding is confirmed in coronary atherosclerotic plaques, where diabetes (which is at least temporarily accompanied by episodes of hyperglycemia) is associated with a significantly greater proportion of CD68⁺AR⁺⁺ macrophages. In the past, the metabolic syndrome comprising both obesity and diabetes mellitus has been found to predominantly induce macrophage M1 polarization.⁴ Accordingly, one could speculate that under these circumstances AR expression may be induced both by predominant M1 polarization of plaque macrophages and episodes of hyperglycemia.

AR has been shown to promote atherosclerosis in hyperglycemic, diabetic Apoe⁻^/⁻ mice.³³ Similar results have been obtained, when human AR was overexpressed in hyperglycemic diabetic Ldlr⁻^/⁻ mice.³⁴ Interestingly, this effect was not seen in normoglycemic Ldlr⁻^/⁻ mice, emphasizing the crucial role of hyperglycemia in the pathophysiologiy of AR-induced atherogenesis. As an underlying mechanism, AR-mediated hyperacetylation of Egr-1, inducing up-regulation of VCAM-1 and tissue factor in aortas of Apoe⁻^/⁻ mice, has been suggested.³⁵ In human macrophages, we have previously shown that low-density lipoprotein and hyperglycemia may synergistically induce AR expression.¹⁵ These data are now complemented by our findings that macrophage M1 polarization is essential for hyperglycemia-induced up-regulation of AR.

In conclusion, we demonstrate that polarization of plaque macrophages may be affected by cardiovascular risk factors such as hyperglycemia. Our data therefore illustrate the complex interplay between systemic and local factors in the pathogenesis of atherosclerotic disease.

Footnotes

Acknowledgments

We thank Dr Klaus Ley (La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA) for providing post-mortem coronary artery specimens; we also acknowledge John Sanders and Nadine Wambsganss for their excellent technical assistance.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the Cardiology Career Program (University of Heidelberg) to G.R., by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research) to H.A.K

References

Galkina

Ley

. Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol 2009; 27: 165–197.

Wolfs

Donners

de Winther

. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost 2011; 106: 763–771.

Chinetti-Gbaguidi

Colin

Staels

. Macrophage subsets in atherosclerosis. Nat Rev Cardiol 2015; 12: 10–17.

Kraakman

Murphy

Jandeleit-Dahm

Kammoun

. Macrophage polarization in obesity and type 2 diabetes: Weighing down our understanding of macrophage function? Front Immunol 2014; 5: 470–470.

Lloyd-Jones

Adams

Brown

. Executive summary: heart disease and stroke statistics—2010 update. Circulation 2010; 121: 948–954.

Gleissner

. The vulnerable vessel. Vascular disease in diabetes mellitus. Hamostaseologie 2015; 35: 267–271.

Gleissner

Galkina

Nadler

Ley

. Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech 2007; 4: 131–140.

Spycher

Tabataba-Vakili

O'Donnell

. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. FASEB J 1997; 11: 181–188.

Spycher

Tabataba-Vakili

O'Donnell

. 4-hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase. Biochem Biophys Res Commun 1996; 226: 512–516.

10.

Inagaki

Miwa

Okuda

. Affinity purification and Glc specificity of aldose reductase from bovine lens. Arch Biochem Biophys 1982; 216: 337–344.

11.

Grimshaw

. Direct measurement of the rate of ring opening of d-Glc by enzyme-catalyzed reduction. Carbohydr Res 1986; 148: 345–348.

12.

Kyselova

Stefek

Bauer

. Pharmacological prevention of diabetic cataract. J Diabetes Complications 2004; 18: 129–140.

13.

Larkins

Dunlop

. The link between hyperglycaemia and diabetic nephropathy. Diabetologia 1992; 35: 499–504.

14.

McHugh

. Diabetes and peripheral sensory neurons: What we don't know and how it can hurt us. AACN Clin Issues 2004; 15: 136–149.

15.

Gleissner

Sanders

Nadler

Ley

. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1137–1143.

16.

Smalley

Root

Cho

. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost 2007; 97: 67–80.

17.

Gleissner

Shaked

Little

Ley

. Cxc chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010; 184: 4810–4818.

18.

Gleissner

Shaked

Erbel

. Cxcl4 downregulates the atheroprotective hemoglobin receptor cd163 in human macrophages. Circ Res 2010; 106: 203–211.

19.

Martinez

Gordon

Locati

Mantovani

. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303–7311.

20.

Chan

Sutphin

Nguyen

. Targeting glut1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011; 3: 94ra70–94ra70.

21.

Wang

Seed

. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003; 31: e154–e154.

22.

Klingenberg

Nofer

Rudling

. Sphingosine-1-phosphate analogue fty720 causes lymphocyte redistribution and hypercholesterolemia in apoe-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 2392–2399.

23.

Wermuth

von Wartburg

. Aldose reductase from human tissues. Methods Enzymol 1982; 89: 181–186.

24.

Nishimura

Matsuura

Kokai

. Cloning and expression of human aldose reductase. J Biol Chem 1990; 265: 9788–9792.

25.

Iwata

Sato

Jimenez

. Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha. J Biol Chem 1999; 274: 7993–8001.

26.

Maianu

Melbert

Garvey

. Facilitative Glc transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for glut isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood cells Mol Dis 2004; 32: 182–190.

27.

Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007 Aug; 6(2): 137--43. PubMed PMID: 17681149.

28.

Waldo

Buono

. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008; 172: 1112–1126.

29.

Boyle

Harrington

Piper

. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009; 174: 1097–1108.

30.

Erbel

Tyka

Helmes

. Cxcl4-induced plaque macrophages can be specifically identified by co-expression of mmp7+s100a8+ in vitro and in vivo. Innate Immun 2015; 21: 255–265.

31.

Erbel

Wolf

Lasitschka

. Prevalence of m4 macrophages within human coronary atherosclerotic plaques is associated with features of plaque instability. Int J Cardiol 2015; 186: 219–225.

32.

Malide

Davies-Hill

Levine

Simpson

. Distinct localization of glut-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation. Am J Physiol 1998; 274: E516–E526.

33.

Vedantham

Noh

Ananthakrishnan

. Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol 2011; 31: 1805–1813.

34.

Vikramadithyan

Noh

. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 2005; 115: 2434–2443.

35.

Vedantham

Thiagarajan

Ananthakrishnan

. Aldose reductase drives hyperacetylation of egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals. Diabetes 2014; 63: 761–774.

Differential regulation of aldose reductase expression during macrophage polarization depends on hyperglycemia

Abstract

Keywords

Introduction

Material and methods

Monocyte-derived human macrophages

Quantitative RT-PCR

Flow cytometry

AR activity assay

Immunofluorescence

Statistics

Results

AR is differentially expressed in human atherosclerotic plaque macrophages

AR is preferentially expressed by M1-polarized macrophages

Differential AR expression between M1 and M2 macrophages depends on hyperglycemia

Diabetic patients display a greater proportion of CD68+AR++ macrophages than non-diabetic patients

Discussion

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Funding

References

Diabetic patients display a greater proportion of CD68⁺AR⁺⁺ macrophages than non-diabetic patients